{"disease":{"id":"dermatographic-urticaria","name":"Dermatographic urticaria","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":22,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"alimemazine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temaril","generic_name":"alimemazine","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"trimeprazine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"doxylamin","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxylamin","company_name":"St. Petersburg Bekhterev Research Psychoneurological Institute","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"dexbrompheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Drixoral","generic_name":"DEXBROMPHENIRAMINE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexbrompheniramine","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"diphenylpyraline","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hispril","generic_name":"DIPHENYLPYRALINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"diphenylpyraline","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"tripelennamine-citrate","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyribenzamin","generic_name":"TRIPELENNAMINE CITRATE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"tripelennamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mepyramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyrilamine","generic_name":"mepyramine","company_name":"Impax Labs","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"antazoline","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenazoline","generic_name":"ANTAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"antazoline","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"chlorpheniramine-maleate","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"CHLORPHENIRAMINE MALEATE","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"hydroxyzine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxyzine Hydrochloride","generic_name":"HYDROXYZINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cyproheptadine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyproheptadine Hydrochloride","generic_name":"CYPROHEPTADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"cyproheptadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doxylamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unisom","generic_name":"DOXYLAMINE","company_name":"Chattem","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antihistamine","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"pecazine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pecazine","company_name":"","drug_phase":"unknown","molecular_target":"5-hydroxytryptamine receptor 6, FAD-linked sulfhydryl oxidase ALR, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methapyrilene","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thenylene","generic_name":"METHAPYRILENE","company_name":"","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"dexchlorpheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexchlorpheniramine Maleate","generic_name":"DEXCHLORPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"dexchlorpheniramine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorphenamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tussionex Pennkinetic","generic_name":"chlorphenamine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"triprolidine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Actidil","generic_name":"TRIPROLIDINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"triprolidine","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"brompheniramine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dimetane-Dx","generic_name":"BROMPHENIRAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"brompheniramine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carbinoxamine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Karbinal Er","generic_name":"CARBINOXAMINE","company_name":"Mcneil","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Histamine-1 Receptor Antagonist","quality_score":70,"revenue":null,"mechanism":"Karbinal Er works by blocking the histamine H1 receptor, a key player in the body's allergic response."},{"drug_id":"azatadine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azatidine","generic_name":"AZATADINE","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"azatadine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clemastine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavist","generic_name":"CLEMASTINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"clemastine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxizine","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxizine","company_name":"King Faisal Specialist Hospital & Research Center","drug_phase":"phase_1","molecular_target":"5-hydroxytryptamine receptor 2A, Cytochrome P450 2D6, D(2) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"clemastin","indication_name":"Dermatographic urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Clemastin","company_name":"Technical University of Munich","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Cytochrome P450 2C19, Solute carrier family 22 member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":22,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}